Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3269 - Biomarkers of immune therapy in CUP

Date

11 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Carcinoma of Unknown Primary Site (CUP)

Presenters

Joanne Xiu

Citation

Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363

Authors

J. Xiu1, Z. Gatalica2

Author affiliations

  • 1 Medical Affairs, Caris Life Sciences, 85040 - Phoenix/US
  • 2 Pathology, Caris Life Sciences, 85040 - phoenix/US
More

Resources

Abstract 3269

Background

Carcinoma of unknown primary (CUP) accounts for approximately 3% of all malignancies. Identification of common cancer pathway alterations (hallmarks of cancer) in diverse cancer lineages offers a rationale for search for biomarkers of targeted therapies in patients with CUP. Avoiding immune destruction is a more recently recognized common cancer characteristic and biomarkers associated with immune check-point blockade were explored in this study.

Methods

392 cases of CUP were tested with NextSeq platform with a 592-gene panel. Tumor mutational load (TML) was calculated using only somatic nonsynonymous missense mutations; microsatellite instability (MSI) was evaluated with NGS by direct analysis of known MSI loci in the target regions of the sequenced genes. ArcherDx FusionPlex Assay was used to detect gene fusions and 52 gene targets were analyzed for 156 tumors. IHC was used to detect tumor expression of PD-L1 (SP142 antibody) and PD-1 TILs (NAT105 antibody) All tests were done in a CLIA-certified lab.

Results

Average patient’s age was 62.4 years; 52% were female. TML high was seen in 12.2% (48/392) tumors using a cutoff of 17 mutations/Mb. MSI-high was detected in 10/392 (2.6%) of tumors. A total of 70 different genes were found mutated with the incidence ranging from 0.3% to 54%; the most frequent were TP53 (53.5%), KRAS (21.5%) and ARID1A (14.6%). Additional notable targetable mutations include PIK3CA (13.1%), CDKN2A (8.1%), PTEN (4.5%), BRAF (4.1%), ATM (3.3%), NOTCH1 (2.4%) and ERBB2 (1.5%). Targetable gene fusions identified included FGFR2 fusions (N = 2), RET (N = 1), RAF1 (N = 1).Tumors with fusions identified carry a lower TML (average 5.9) than the complete cohort (11.7, p 

Conclusions

Using a multiplex testing approach, 28% of CUPs had biomarkers (TML-H, MSI-H and/or PD-L1) of response to the immune check-point blockade were identified, making CUP one of the most likely candidate to benefit from immune checkpoint inhibitors.

Clinical trial identification

Legal entity responsible for the study

Joanne Xiu

Funding

None

Disclosure

J. Xiu, Z. Gatalica: Employee of Caris Life Sciences.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.